|
Report No. : |
331422 |
|
Report Date : |
08.07.2015 |
IDENTIFICATION DETAILS
|
Name : |
SUMMIT
PHARMACEUTICALS INTERNATIONAL CORPORATION |
|
|
|
|
Registered Office : |
Harumi Triton Square Office Tower Z Bldg 23F, 1-8-12 Harumi Chuoku Tokyo, 104-0053 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.03.2015 |
|
|
|
|
Date of Incorporation : |
November 1949 |
|
|
|
|
Com. Reg. No.: |
0100-01-103866 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Imports, exports and wholesales: pharmaceuticals (raw materials, intermediates, finished products), animal drugs, foods & food additives (synthetic dyestuffs, pigments), quasi-medicines, cosmetics, chemicals, biochemical, agro-chemicals, medical instruments, others (--100%) |
|
|
|
|
No. of Employees : |
131 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
JAPAN - ECONOMIC OVERVIEW
In the years following World War II, government-industry
cooperation, a strong work ethic, mastery of high technology, and a
comparatively small defense allocation (1% of GDP) helped Japan develop an
advanced economy. Two notable characteristics of the post-war economy were the
close interlocking structures of manufacturers, suppliers, and distributors,
known as keiretsu, and the guarantee of lifetime employment for a substantial
portion of the urban labor force. Both features are now eroding under the dual
pressures of global competition and domestic demographic change. Scarce in many
natural resources, Japan has long been dependent on imported raw materials.
Since the complete shutdown of Japan’s nuclear reactors after the earthquake
and tsunami disaster in 2011, Japan's industrial sector has become even more
dependent than it was previously on imported fossil fuels. A small agricultural
sector is highly subsidized and protected, with crop yields among the highest
in the world. While self-sufficient in rice production, Japan imports about 60%
of its food on a caloric basis. For three decades, overall real economic growth
had been impressive - a 10% average in the 1960s, a 5% average in the 1970s,
and a 4% average in the 1980s. Growth slowed markedly in the 1990s, averaging
just 1.7%, largely because of the aftereffects of inefficient investment and an
asset price bubble in the late 1980s that required a protracted period of time
for firms to reduce excess debt, capital, and labor. Modest economic growth
continued after 2000, but the economy has fallen into recession four times
since 2008. Government stimulus spending helped the economy recover in late
2009 and 2010, but the economy contracted again in 2011 as the massive 9.0
magnitude earthquake and the ensuing tsunami in March of that year disrupted
manufacturing. The economy has largely recovered in the four years since the
disaster, although reconstruction in the affected Tohoku region has lagged, in
part due to a shortage of labor in the construction sector. Japan enjoyed a
sharp uptick in growth in 2013 on the basis of Prime Minister Shinzo Abe’s
“Three Arrows” economic revitalization agenda - dubbed “Abenomics” - of
monetary easing, “flexible” fiscal policy, and structural reform. Abe’s
government has replaced the preceding administration’s plan to phase out
nuclear power with a new policy of seeking to restart nuclear power plants that
meet strict new safety standards, and emphasizing nuclear energy’s importance
as a base-load electricity source. Japan joined the Trans-Pacific Partnership
(TPP) negotiations in 2013, a pact that would open Japan's economy to increased
foreign competition and create new export opportunities for Japanese
businesses. Measured on a purchasing power parity (PPP) basis that adjusts for
price differences, Japan in 2014 stood as the fourth-largest economy in the
world after second-place China, which surpassed Japan in 2001, and third-place
India, which edged out Japan in 2012. While seeking to stimulate and reform the
economy, the government must also devise a strategy for reining in Japan's huge
government debt, which amounts to more than 230% of GDP. To help raise
government revenue, Japan adopted legislation in 2012 to gradually raise the
consumption tax rate to 10% by 2015, beginning with a hike from 5% to 8%
implemented in April 2014. That increase had a contractionary effect on GDP,
however, so PM Abe in late 2014 decided to postpone the final phase of the
increase until April 2017 to give the economy more time to recover. Led by the
Bank of Japan’s aggressive monetary easing, Japan is making progress in ending
deflation, but demographics - low birthrate and an aging, shrinking population
- pose major long-term challenges for the economy.
|
Source
: CIA |
SUMMIT PHARMACEUTICALS INTERNATIONAL CORPORATION
REGD NAME: Sumisho
Pharma International KK
MAIN OFFICE: Harumi
Triton Square Office Tower Z Bldg 23F, 1-8-12 Harumi Chuoku Tokyo
104-0053 JAPAN
Tel: 03-3536-8611
Fax: 03-3536-8619
URL: http://www.summitpharma.co.jp
E-Mail address: info@summitpharma.co.jp
ACTIVITIES: Import,
export, wholesale of pharmaceuticals, chemicals, food additives, other
BRANCHES: Osaka,
Yokohama, Kawasaki
OVERSEAS: Europe,
China; also 115 overseas offices in 68 countries of the parent utilized
FACTORIES: Kawasaki
(API Laboratory)
OFFICERS: YOSHIKI
TERAWAKI, PRES Heizo Suzuki, dir
Shun’ya Kitamura,
dir Michinobu Yugen, dir
Ken’ichi Nakamura, dir
Yen Amount: In million Yen, unless otherwise stated
FINANCES FAIR A/SALES Yen 20,474 M
PAYMENTSREGULAR CAPITAL Yen 480 M
TREND STEADY WORTH Yen 3,102 M
STARTED 1949 EMPLOYES 131
COMMENT: TRADING FIRM SPECIALIZING IN PHARMACEUTICALS, OTHER, OWNED BY SUMITOMO CORPORATION. FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS AND RESPONSIBLE FOR CREDIT ENGAGEMENTS: US$300,000/O/A 45 DAYS.
The subject company was established by Sumitomo Corp (See REGISTRATION) as Summit Medi-Chem Corp,
and in Oct 2006 merged with Summit Pharmaceuticals International Corporation
and started anew. This is a trading firm
for import, export and wholesale of pharmaceuticals, food additives, agro
chemicals, cosmetics, bio chemicals, other (See OPERATION). Sole import
agent of ATTC of USA. Clients include
major pharmaceutical mfrs.
The sales volume for Mar/2015 fiscal term amounted to Yen 20,474 million, a 25% up from Yen 16,318 million in the previous term. The recurring profit was posted at Yen 1,115 million and the net profit at Yen 720 million, respectively, compared with Yen 869 million recurring profit and Yen 2,465 million net profit, respectively, a year ago.
For the current term ending Mar 2016 the recurring profit is projected at Yen 1,170 million and the net profit at Yen 750 million, respectively, on a 5% rise in turnover, to Yen 21,500 million. The weaker Yen will raise import/export earnings in Yen terms.
The financial situation is considered FAIR and good for
ORDINARY business engagements.
Date Registered: Nov 1949
Regd No.:
0100-01-103866
(Tokyo-Chuoku)
Legal Status: Limited
Company (Kabushiki Kaisha)
Authorized: 5.6
million shares
Issued: 1.4
million shares
Sum: Yen
480 million
Major
shareholders (%): Sumitomo Corp* (100)
*.. One of leading
general trading houses, Tokyo, founded 1919, listed Tokyo S/E, capital Yen
219,279 million, turnover Yen 3,762,236 million, operating loss Yen 84,374
million, recurring loss Yen 18,561 million, net loss Yen 73,170 million, total
assets Yen 9,021,370 million, net worth Yen 2,481,432 million, employees
75,448, pres Kuniharu Nakamura
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Imports, exports and wholesales: pharmaceuticals (raw materials, intermediates, finished products), animal drugs, foods & food additives (synthetic dyestuffs, pigments), quasi-medicines, cosmetics, chemicals, biochemical, agro-chemicals, medical instruments, others (--100%)
Clients: [Mfrs, wholesalers] Sawai Pharmaceutical, Daiichi Sankyo Co, Kyorin Holdings Inc, Nippon Kayaku Co, Astellas Pharma Tech Co, Kyoritsu Seiyaku Corp, Daiichi Sankyo Propharma, Teikoku Seiyaku Co, Takeda Pharmaceutical, Nabelin Co, other
No. of accounts: 500
Domestic areas of activities: Nationwide
Suppliers: [Mfrs, wholesalers] Sumitomo Corp Korea, Summit Pharmaceuticals Europe Ltd, Asahi Kasei Chemicals, Orion Corp, Orion Pharma, Perkinermer Health Science, ATTC, Sumitomo Seika Chemicals, Sumitomo Bakelite Co, Koei Chemical Co, Kawaken Fine Chemicals, Sumitomo Corp China, other
Payment record: Regular
Location: Business area in
Tokyo. Office premises at the caption
address are leased and maintained satisfactory.
Bank References:
SMBC (Tokyo)
MUFG (Jinbocho)
Relations:
Satisfactory
(In Million
Yen)
|
Terms Ending: |
31/03/2016 |
31/03/2015 |
31/03/2014 |
31/03/2013 |
|
|
Annual
Sales |
|
21,500 |
20,474 |
16,318 |
16,595 |
|
Recur.
Profit |
|
1,170 |
1,115 |
869 |
1,622 |
|
Net
Profit |
|
750 |
720 |
2,465 |
201 |
|
Total
Assets |
|
|
10,716 |
9,301 |
7,984 |
|
Current
Assets |
|
|
7,533 |
8,628 |
7,359 |
|
Current
Liabs |
|
|
612 |
4,380 |
4,817 |
|
Net
Worth |
|
|
3,102 |
4,837 |
3,065 |
|
Capital,
Paid-Up |
|
|
480 |
480 |
480 |
|
Div.Ttl
in Million (¥) |
|
|
2,436 |
715.4 |
609 |
|
<Analytical Data> |
|
(%) |
(%) |
(%) |
(%) |
|
S.Growth Rate |
|
5.01 |
25.47 |
-1.67 |
3.39 |
|
Current Ratio |
|
.. |
1,230.88 |
196.99 |
152.77 |
|
N.Worth Ratio |
|
.. |
28.95 |
52.01 |
38.39 |
|
R.Profit/Sales |
|
5.44 |
5.45 |
5.33 |
9.77 |
|
N.Profit/Sales |
|
3.49 |
3.52 |
15.11 |
1.21 |
|
Return On Equity |
|
.. |
23.21 |
50.96 |
6.56 |
Notes: Forecast
(or estimated) figures for the 31/03/2016 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.37 |
|
|
1 |
Rs.98.86 |
|
Euro |
1 |
Rs.69.97 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.